JPS4941379A - - Google Patents

Info

Publication number
JPS4941379A
JPS4941379A JP48056234A JP5623473A JPS4941379A JP S4941379 A JPS4941379 A JP S4941379A JP 48056234 A JP48056234 A JP 48056234A JP 5623473 A JP5623473 A JP 5623473A JP S4941379 A JPS4941379 A JP S4941379A
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP48056234A
Other languages
Japanese (ja)
Other versions
JPS547794B2 (Direct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPS4941379A publication Critical patent/JPS4941379A/ja
Publication of JPS547794B2 publication Critical patent/JPS547794B2/ja
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP5623473A 1972-05-19 1973-05-19 Expired JPS547794B2 (Direct)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (Direct) 1972-05-19 1972-05-19

Publications (2)

Publication Number Publication Date
JPS4941379A true JPS4941379A (Direct) 1974-04-18
JPS547794B2 JPS547794B2 (Direct) 1979-04-10

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5623473A Expired JPS547794B2 (Direct) 1972-05-19 1973-05-19

Country Status (17)

Country Link
US (1) US3928326A (Direct)
JP (1) JPS547794B2 (Direct)
BE (1) BE799728A (Direct)
CA (1) CA1003402A (Direct)
CY (1) CY1012A (Direct)
DE (1) DE2323216C3 (Direct)
DK (1) DK133249C (Direct)
FI (1) FI50711C (Direct)
FR (1) FR2185406B1 (Direct)
GB (1) GB1428416A (Direct)
HK (1) HK49079A (Direct)
IL (1) IL42154A (Direct)
KE (1) KE2969A (Direct)
NL (1) NL175917C (Direct)
SE (1) SE378110B (Direct)
SU (1) SU468408A3 (Direct)
ZA (1) ZA732956B (Direct)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57122100A (en) * 1980-12-04 1982-07-29 Draco Ab 4-pregnene derivative and manufacture
JPS6140299A (ja) * 1984-06-11 1986-02-26 シコ−ル　ソシエテ　イタリア−ナ　コルテイコステロイデイ　エス・ピ−・エ− プレグナン誘導体の１６，１７―アセタール類の製造方法
JPS62281817A (ja) * 1975-05-27 1987-12-07 シンテツクス，（ユ−，エス，エイ）　インコ−ポレ−テツド 鼻用噴霧液

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
PL178307B1 (pl) * 1993-01-08 2000-04-28 Astra Ab Nowe pochodne steroidowe, sposób wytwarzania nowych pochodnych steroidowych i preparat farmaceutyczny do leczenia stanu zapalnego śluzówki jelita
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
BRPI0413330A (pt) * 2003-08-29 2006-10-10 Ranbaxy Lab Ltd inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1737861A4 (en) 2004-04-09 2010-04-28 Merck Sharp & Dohme HEMMER OF ACT ACTIVITY
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1948164A1 (en) 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of muscarinic receptor antagonists
US20090054382A1 (en) * 2005-10-19 2009-02-26 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP2086948A2 (en) * 2006-09-22 2009-08-12 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RU2446796C2 (ru) 2006-12-26 2012-04-10 Фармасайкликс, Инк. Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
SI2124944T1 (sl) 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
GEP20146135B (en) * 2009-09-11 2014-08-11 Chiesi Farm Spa Pregnane derivatives condensed in 16, 17 position with n-substituted isoxazolidine ring as anti-inflammatory agents
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2534145A4 (en) 2010-02-08 2013-09-11 Kinagen Inc THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
DK2606134T3 (da) 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CA2831730A1 (en) 2011-04-21 2012-10-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
ES2691643T3 (es) 2012-08-24 2018-11-28 Board Of Regents, The University Of Texas System Moduladores heterocíclicos de la actividad de HIF para el tratamiento de enfermedades
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
KR20250114431A (ko) 2016-11-08 2025-07-29 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
IL319417A (en) 2018-01-08 2025-05-01 Regeneron Pharma Steroids and their anti-inflammatory properties
MX2020011546A (es) 2018-05-09 2021-01-29 Regeneron Pharma Anticuerpos anti-msr1 y metodos de uso de los mismos.
JP7446282B2 (ja) 2018-08-07 2024-03-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4076460A4 (en) 2019-12-17 2023-11-15 Merck Sharp & Dohme LLC PRMT5 INHIBITORS
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
US20230108452A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
AU2023336062A1 (en) 2022-09-02 2025-03-13 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
US20240208987A1 (en) 2022-10-25 2024-06-27 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
KR20250116773A (ko) 2022-12-14 2025-08-01 머크 샤프 앤드 돔 엘엘씨 아우리스타틴 링커-페이로드, 제약 조성물, 및 그의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62281817A (ja) * 1975-05-27 1987-12-07 シンテツクス，（ユ−，エス，エイ）　インコ−ポレ−テツド 鼻用噴霧液
JPS57122100A (en) * 1980-12-04 1982-07-29 Draco Ab 4-pregnene derivative and manufacture
JPS6140299A (ja) * 1984-06-11 1986-02-26 シコ−ル　ソシエテ　イタリア−ナ　コルテイコステロイデイ　エス・ピ−・エ− プレグナン誘導体の１６，１７―アセタール類の製造方法

Also Published As

Publication number Publication date
NL175917C (nl) 1985-01-16
JPS547794B2 (Direct) 1979-04-10
IL42154A (en) 1976-12-31
SU468408A3 (ru) 1975-04-25
FI50711B (Direct) 1976-03-01
DK133249B (da) 1976-04-12
IL42154A0 (en) 1973-07-30
GB1428416A (en) 1976-03-17
ZA732956B (en) 1974-04-24
BE799728A (fr) 1973-09-17
AU5525273A (en) 1974-11-07
US3928326A (en) 1975-12-23
FR2185406A1 (Direct) 1974-01-04
NL175917B (nl) 1984-08-16
FR2185406B1 (Direct) 1976-12-31
CY1012A (en) 1979-11-23
DE2323216C3 (de) 1978-06-22
KE2969A (en) 1979-07-20
DE2323216A1 (de) 1973-11-29
HK49079A (en) 1979-07-27
DK133249C (da) 1976-09-13
DE2323216B2 (de) 1977-11-03
FI50711C (fi) 1976-06-10
NL7306979A (Direct) 1973-11-21
CA1003402A (en) 1977-01-11
SE378110B (Direct) 1975-08-18

Similar Documents

Publication Publication Date Title
FR2185406A1 (Direct)
BE805587A (Direct)
BG18316A1 (Direct)
BG18318A1 (Direct)
CH1123872A4 (Direct)
CH1200672A4 (Direct)
CH133573A4 (Direct)
CH1570373A4 (Direct)
CH1830472A4 (Direct)
CH267573A4 (Direct)
CH392772A4 (Direct)
CH556053A (Direct)
CH559500A5 (Direct)
CH559550A5 (Direct)
CH559902A5 (Direct)
CH560870A5 (Direct)
CH562640A5 (Direct)
CH562753A5 (Direct)
CH563621A5 (Direct)
CH564776A5 (Direct)
CH566453A5 (Direct)
CH566523A5 (Direct)
CH568551A5 (Direct)
CH569143A5 (Direct)
CH572024A5 (Direct)